US5476932A
(en)
*
|
1994-08-26 |
1995-12-19 |
Hoffmann-La Roche Inc. |
Process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives
|
EP0882734B1
(en)
*
|
1997-06-02 |
2009-08-26 |
F. Hoffmann-La Roche Ag |
5'-Deoxy-cytidine derivatives
|
NZ330360A
(en)
*
|
1997-06-02 |
1999-03-29 |
Hoffmann La Roche |
5'-deoxy-cytidine derivatives, their manufacture and use as antitumoral agents
|
US6005098A
(en)
*
|
1998-02-06 |
1999-12-21 |
Hoffmann-La Roche Inc. |
5'deoxycytidine derivatives
|
PL348673A1
(en)
*
|
1998-09-25 |
2002-06-03 |
Warner Lambert Co |
Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin
|
US20070122481A1
(en)
*
|
1998-11-02 |
2007-05-31 |
Elan Corporation Plc |
Modified Release Compositions Comprising a Fluorocytidine Derivative for the Treatment of Cancer
|
US20080113025A1
(en)
*
|
1998-11-02 |
2008-05-15 |
Elan Pharma International Limited |
Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
|
CZ298259B6
(cs)
|
2000-02-28 |
2007-08-08 |
Aventis Pharma S. A. |
Farmaceutická kombinace k lécení rakoviny obsahující CPT-11 a capecitabin
|
AU2001246863A1
(en)
*
|
2000-04-11 |
2001-10-23 |
Sayuri Yamada |
Curcumin compositions
|
KR100631754B1
(ko)
*
|
2000-08-09 |
2006-10-09 |
주식회사 코오롱 |
N-알킬옥시카르보닐-5-플루오로사이토신 유도체 및 그의제조방법
|
KR100730768B1
(ko)
*
|
2000-08-09 |
2007-06-21 |
코오롱생명과학 주식회사 |
5'-데옥시-n-알킬옥시카르보닐-5-플루오로사이토신-5'-카르복실산 및 그 유도체와 이들의 제조방법
|
GB0113374D0
(en)
*
|
2001-06-04 |
2001-07-25 |
Jerram Clare |
Washing line umbrella
|
US20060089327A1
(en)
*
|
2002-01-14 |
2006-04-27 |
Hohneker John A |
Combinations comprising epothilones and anti-metabolites
|
CN1649614A
(zh)
|
2002-02-22 |
2005-08-03 |
新河药品股份有限公司 |
活性剂传递系统和保护及施用活性剂的方法
|
AU2003274576A1
(en)
*
|
2002-11-15 |
2004-06-15 |
Warner-Lambert Company Llc |
Combination chemotherapy comprising a mek inhibitor and capecitabine for treating cancer
|
AU2003233586A1
(en)
*
|
2003-05-20 |
2005-01-21 |
Aronex Pharmaceuticals, Inc. |
Combination chemotherapy comprising capecitabine and a liposomal platinum complex
|
CA2544320A1
(en)
*
|
2003-11-13 |
2005-06-02 |
Pharma Mar, S.A.U. |
Method of treating cancer using a combination comprising et-743 and 5-fluorouracil
|
DK1706414T3
(da)
*
|
2003-12-22 |
2008-10-13 |
Hoffmann La Roche |
Fremgangsmåde til fluorcytidinderivater
|
JP2008528695A
(ja)
|
2005-02-03 |
2008-07-31 |
ザ ジェネラル ホスピタル コーポレーション |
ゲフィチニブ耐性癌を治療する方法
|
EP1868608A2
(en)
*
|
2005-04-01 |
2007-12-26 |
F. Hoffmann-Roche AG |
Method for administration of capecitabine
|
KR20080035630A
(ko)
|
2005-07-18 |
2008-04-23 |
바이파 사이언스 인코포레이티드 |
암의 치료
|
CA2616008A1
(en)
|
2005-07-21 |
2007-01-25 |
Stefan Meuer |
Stabilized chlorite solutions in combination with fluoropyrimidines for cancer treatment.
|
CN103110948A
(zh)
|
2005-11-04 |
2013-05-22 |
惠氏公司 |
mTOR抑制剂、赫赛汀和/或HKI-272的抗肿瘤组合
|
SG10202003901UA
(en)
|
2005-12-13 |
2020-05-28 |
Incyte Holdings Corp |
Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
|
US20100160442A1
(en)
*
|
2006-07-18 |
2010-06-24 |
Ossovskaya Valeria S |
Formulations for cancer treatment
|
US20080085310A1
(en)
*
|
2006-10-06 |
2008-04-10 |
Maria Oksana Bachynsky |
Capecitabine rapidly disintegrating tablets
|
CN100425617C
(zh)
*
|
2006-10-31 |
2008-10-15 |
浙江海正药业股份有限公司 |
一种含氟嘧啶类化合物烷氧羰酰化的方法
|
ITMI20070435A1
(it)
|
2007-03-05 |
2008-09-06 |
Innovate Biotechnology Srl |
2',3'-di-o-acil-5-fluoronucleosidi
|
JP2010524960A
(ja)
*
|
2007-04-20 |
2010-07-22 |
ドクター・レディーズ・ラボラトリーズ・リミテッド |
カペシタビンを調製するためのプロセス
|
WO2008145403A1
(en)
*
|
2007-06-01 |
2008-12-04 |
Synthon B.V. |
Processes related to making capecitabine
|
CN103524509B
(zh)
|
2007-06-13 |
2016-03-02 |
因塞特控股公司 |
詹纳斯激酶抑制剂(R)-3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈的盐
|
US7842675B2
(en)
*
|
2007-09-15 |
2010-11-30 |
Protia, Llc |
Deuterium-enriched capecitabine
|
US8741858B2
(en)
*
|
2007-09-21 |
2014-06-03 |
Zhongxu Ren |
Oligomer-nucleoside phosphate conjugates
|
US8022216B2
(en)
|
2007-10-17 |
2011-09-20 |
Wyeth Llc |
Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
|
KR101013312B1
(ko)
*
|
2007-11-19 |
2011-02-09 |
한미홀딩스 주식회사 |
카페시타빈의 제조방법 및 이에 사용되는 β-아노머가강화된 트리알킬카보네이트 화합물의 제조방법
|
AR064165A1
(es)
|
2007-12-06 |
2009-03-18 |
Richmond Sa Com Ind Y Financie |
Un procedimiento para la preparacion de capecitabina e intermediarios utilizables en dicho procedimiento
|
KR20090122955A
(ko)
*
|
2008-01-03 |
2009-12-01 |
플러스 케미칼스, 에스.에이. |
카페시타빈의 제조 방법
|
US20090311335A1
(en)
*
|
2008-06-12 |
2009-12-17 |
Scott Jenkins |
Combination of a triptan and an nsaid
|
US20090312360A1
(en)
|
2008-06-17 |
2009-12-17 |
Wyeth |
Antineoplastic Combinations Containing HKI-272 and Vinorelbine
|
RU2498804C2
(ru)
|
2008-08-04 |
2013-11-20 |
ВАЙЕТ ЭлЭлСи |
Противоопухолевые комбинации из 4-анилино-3-цианохинолинов и капецитабина
|
EP2370414A4
(en)
*
|
2008-12-02 |
2012-11-14 |
Reddys Lab Ltd Dr |
PREPARATION OF CAPECITABINE
|
EP2393472B1
(en)
*
|
2008-12-05 |
2019-06-05 |
NanoMed Holdings Pty Ltd |
Amphiphile prodrugs
|
HRP20230315T1
(hr)
|
2009-04-06 |
2023-05-12 |
Wyeth Llc |
Režim liječenja raka dojke korištenjem neratiniba
|
FR2945211A1
(fr)
|
2009-05-06 |
2010-11-12 |
Sanofi Aventis |
Combinaison antitumorale comprenant la cabazitaxel et la capecitabine
|
ES2761300T3
(es)
|
2009-05-22 |
2020-05-19 |
Incyte Holdings Corp |
3-[4-(7H-pirrolo[2,3-d]pirimidina-4-ilo)-1H-pirazol-1-ilo]octano- o heptano-nitrilo como inhibidores de JAK
|
KR20120037932A
(ko)
*
|
2009-07-23 |
2012-04-20 |
시노팜 타이완 리미티드 |
플루오로시티딘 유도체를 제조하는 방법
|
WO2011067588A1
(en)
|
2009-12-04 |
2011-06-09 |
Generics [Uk] Limited |
Cyclic sulphinyl esters of cytidine
|
WO2011104540A1
(en)
*
|
2010-02-24 |
2011-09-01 |
Generics [Uk] Limited |
One step process for the preparation of capecitabine
|
KR102354472B1
(ko)
|
2010-03-10 |
2022-01-21 |
인사이트 홀딩스 코포레이션 |
Jak1 저해제로서의 피페리딘4일 아제티딘 유도체
|
DK2835053T3
(en)
|
2010-03-12 |
2016-08-15 |
Genzyme Corp |
Combination therapy to treat breast cancer
|
UA111588C2
(uk)
|
2010-05-21 |
2016-05-25 |
Інсайт Холдінгс Корпорейшн |
Композиція інгібітора jak для місцевого застосування
|
CN102260309B
(zh)
*
|
2010-05-24 |
2014-10-22 |
重庆福安药业(集团)股份有限公司 |
一种高纯度卡培他滨的制备方法
|
AR083933A1
(es)
|
2010-11-19 |
2013-04-10 |
Incyte Corp |
Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
|
CN102558262A
(zh)
*
|
2010-12-23 |
2012-07-11 |
天津泰普药品科技发展有限公司 |
一种高纯度卡培他滨的制备方法
|
EP2721028B1
(en)
|
2011-06-20 |
2015-11-04 |
Incyte Corporation |
Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
|
CN102266303A
(zh)
*
|
2011-07-07 |
2011-12-07 |
程雪翔 |
一种卡培他滨药用组合物及其制备方法
|
UA111854C2
(uk)
|
2011-09-07 |
2016-06-24 |
Інсайт Холдінгс Корпорейшн |
Способи і проміжні сполуки для отримання інгібіторів jak
|
CN102516338B
(zh)
*
|
2011-12-09 |
2014-04-02 |
海南锦瑞制药股份有限公司 |
一种卡培他滨化合物、其药物组合物及其制备方法
|
TWI560195B
(en)
*
|
2012-01-13 |
2016-12-01 |
Pharmaessentia Corp |
Novel synthesis of 5-deoxy-5'-fluorocytidine compounds
|
PL2919766T3
(pl)
|
2012-11-15 |
2021-10-04 |
Incyte Holdings Corporation |
Postacie dawkowania ruksolitynibu o przedłużonym uwalnianiu
|
PL3489239T3
(pl)
|
2013-03-06 |
2022-03-07 |
Incyte Holdings Corporation |
Sposoby i związki pośrednie dla wytwarzania inhibitora jak
|
AU2014305989B2
(en)
|
2013-08-07 |
2019-11-28 |
Incyte Holdings Corporation |
Sustained release dosage forms for a JAK1 inhibitor
|
JP2016528288A
(ja)
*
|
2013-08-20 |
2016-09-15 |
インサイト・コーポレイションIncyte Corporation |
上昇したc反応性タンパク質レベルを有する固形腫瘍の患者における延命効果
|
EP2883959A1
(en)
|
2013-12-13 |
2015-06-17 |
Plasmia Biotech, S.L. |
Enzymatic production of cytosinic nucleoside analogues
|
CN103897006A
(zh)
*
|
2013-12-18 |
2014-07-02 |
吉林修正药业新药开发有限公司 |
一种卡培他滨异构体的制备方法
|
WO2015191563A1
(en)
|
2014-06-09 |
2015-12-17 |
Lipomedix Pharmaceuticals Ltd. |
Combination chemotherapy comprising a liposomal prodrug of mitomycin c
|
CN104530164A
(zh)
*
|
2014-12-31 |
2015-04-22 |
辰欣药业股份有限公司 |
一种卡培他滨的合成工艺
|
KR20160117060A
(ko)
|
2015-03-31 |
2016-10-10 |
이승주 |
유아용 탁자
|
CN105646625B
(zh)
*
|
2015-12-29 |
2019-06-11 |
江苏吴中医药集团有限公司 |
一种卡培他滨的制备方法
|
US11584733B2
(en)
|
2017-01-09 |
2023-02-21 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human disease
|
EP3565549B1
(en)
|
2017-01-09 |
2022-03-09 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human disease
|
TR201702500A2
(tr)
*
|
2017-02-20 |
2017-07-21 |
Anadolu Ueniversitesi |
Serani̇b-2?ni̇n akci̇ğer kanseri̇ ve meme kanseri̇ni̇n tedavi̇si̇nde kullanimi
|
US10435429B2
(en)
|
2017-10-03 |
2019-10-08 |
Nucorion Pharmaceuticals, Inc. |
5-fluorouridine monophosphate cyclic triester compounds
|
TW201924683A
(zh)
|
2017-12-08 |
2019-07-01 |
美商英塞特公司 |
用於治療骨髓增生性贅瘤的低劑量組合療法
|
CA3087565A1
(en)
|
2018-01-09 |
2019-07-18 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human disease
|
WO2019143860A1
(en)
*
|
2018-01-19 |
2019-07-25 |
Nucorion Pharmaceuticals, Inc. |
5-fluorouracil compounds
|
US11427550B2
(en)
|
2018-01-19 |
2022-08-30 |
Nucorion Pharmaceuticals, Inc. |
5-fluorouracil compounds
|
UA127488C2
(uk)
|
2018-01-30 |
2023-09-06 |
Інсайт Корпорейшн |
Способи одержання (1-(3-фтор-2-(трифторметил)ізонікотиноїл)піперидин-4-ону)
|
FI3773593T3
(fi)
|
2018-03-30 |
2024-06-18 |
Incyte Corp |
Hidradenitis suppurativan hoito jak-estäjiä käyttäen
|
CA3126211A1
(en)
|
2019-01-11 |
2020-07-16 |
Lipomedix Pharmaceuticals Ltd. |
Liposome composition comprising liposomal prodrug of mitomycin c and method of manufacture
|
CN115605492A
(zh)
|
2020-04-21 |
2023-01-13 |
配体制药股份有限公司(Us) |
核苷酸前药化合物
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|
WO2023177894A1
(en)
|
2022-03-18 |
2023-09-21 |
Ideaya Biosciences, Inc. |
Combination therapy comprising a mat2a inhibitor and an antimetabolite agent
|
EP4382093A1
(en)
|
2022-12-05 |
2024-06-12 |
a Fine House S.A. |
Oral suspensions comprising capecitabine
|